Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DOC stock price vs UDR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at UDR's multiple
Needs Annual EPS, UDR P/E.
Implied fair value · at DOC's multiple
Needs Annual EPS, DOC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HEALTHPEAK PROPERTIES, INC. · implied price per share
Reporting currency could not be verified.
UDR, Inc. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
DOC · not enough data.
UDR · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WELLTOWER INC.
DOC vs WELL
Ventas, Inc.
DOC vs VTR
ALEXANDRIA REAL ESTATE EQUITIES, INC.
DOC vs ARE
SL GREEN REALTY CORP
DOC vs SLG
EQUITY RESIDENTIAL
DOC vs EQR
AVALONBAY COMMUNITIES INC
DOC vs AVB
CAMDEN PROPERTY TRUST
DOC vs CPT
MID AMERICA APARTMENT COMMUNITIES INC.
DOC vs MAA
APARTMENT INVESTMENT & MANAGEMENT CO
DOC vs AIV
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DOC can materially expand margins and reduce leverage from its current 14.5x net debt/EBITDA, then hold or buy on weakness; otherwise, the current $20.50 price looks difficult to justify versus UDR and the model-implied $3.46 valuation because DOC's profitability and balance-sheet quality are materially weaker.
DOC screens far below UDR on a P/E basis only because its earnings are much lower relative to price, not because it is obviously cheaper on other measures. On EV/EBITDA and net leverage, DOC also looks less attractive, and the implied price of $3.46 is far below both the current $20.50 price and the stated historical band.
Supporting Metrics
